TRIF Is Required for TLR4 Mediated Adjuvant Effects on T Cell Clonal Expansion

PLoS ONE

Volumn 8, Issue 2, 2013, Pages

  Gandhapudi, Siva K ^a   Chilton, Paula M ^a   Mitchell, Thomas C ^a  

^a University of Louisville School of Medicine   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADAPTOR PROTEIN; CD40 ANTIGEN; CD86 ANTIGEN; INTERFERON; LIPID A; MYELOID DIFFERENTIATION FACTOR 88; TOLL INTERLEUKIN 1 RECEPTOR DOMAIN CONTAINING ADAPTER INDUCING INTERFERON BETA; TOLL LIKE RECEPTOR 4; UNCLASSIFIED DRUG;

ADOPTIVE TRANSFER; ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; CELL DIVISION; CELL EXPANSION; CELL MATURATION; CELL SURVIVAL; CONTROLLED STUDY; CYTOKINE PRODUCTION; DENDRITIC CELL; EX VIVO STUDY; FLOW CYTOMETRY; IN VIVO STUDY; LYMPHOCYTE ACTIVATION; LYMPHOCYTE PROLIFERATION; MOUSE; NONHUMAN; PROTEIN DEFICIENCY; REGULATORY MECHANISM; SIGNAL TRANSDUCTION; T LYMPHOCYTE; UPREGULATION;

ADAPTOR PROTEINS, VESICULAR TRANSPORT; ADJUVANTS, IMMUNOLOGIC; ANIMALS; CELL DIVISION; CELL PROLIFERATION; CHEMOKINES; CLONE CELLS; INTERFERON TYPE I; LIPID A; MICE; SIGNAL TRANSDUCTION; T-LYMPHOCYTES; TOLL-LIKE RECEPTOR 4;

EID: 84874033208     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0056855     Document Type: Article

References (59)

1. Ohashi K, Burkart V, Flohe S, Kolb H, (2000) Cutting edge: heat shock protein 60 is a putative endogenous ligand of the toll-like receptor-4 complex. J Immunol 164: 558-561.
2. Yang D, Postnikov YV, Li Y, Tewary P, de la Rosa G, et al. (2012) High-mobility group nucleosome-binding protein 1 acts as an alarmin and is critical for lipopolysaccharide-induced immune responses. J Exp Med 209: 157-171.
3. Palsson-McDermott EM, O'Neill LA, (2004) Signal transduction by the lipopolysaccharide receptor, Toll-like receptor-4. Immunology 113: 153-162.
4. Chang ZL, (2010) Important aspects of Toll-like receptors, ligands and their signaling pathways. Inflamm Res 59: 791-808.
5. Casella CR, Mitchell TC, (2008) Putting endotoxin to work for us: monophosphoryl lipid A as a safe and effective vaccine adjuvant. Cell Mol Life Sci 65: 3231-3240.
6. Hoebe K, Du X, Georgel P, Janssen E, Tabeta K, et al. (2003) Identification of Lps2 as a key transducer of MyD88-independent TIR signalling. Nature 424: 743-748.
7. Yamamoto M, Akira S, (2010) Lipid A receptor TLR4-mediated signaling pathways. Adv Exp Med Biol 667: 59-68.
8. Weighardt H, Jusek G, Mages J, Lang R, Hoebe K, et al. (2004) Identification of a TLR4- and TRIF-dependent activation program of dendritic cells. Eur J Immunol 34: 558-564.
9. Kaisho T, Akira S, (2002) Toll-like receptors as adjuvant receptors. Biochim Biophys Acta 1589: 1-13.
10. Ulrich JT, Myers KR, (1995) Monophosphoryl lipid A as an adjuvant. Past experiences and new directions. Pharm Biotechnol 6: 495-524.
11. Alderson MR, McGowan P, Baldridge JR, Probst P, (2006) TLR4 agonists as immunomodulatory agents. J Endotoxin Res 12: 313-319.
12. Johnson DA, (2008) Synthetic TLR4-active glycolipids as vaccine adjuvants and stand-alone immunotherapeutics. Curr Top Med Chem 8: 64-79.
13. Garcon N, Van Mechelen M, (2011) Recent clinical experience with vaccines using MPL- and QS-21-containing adjuvant systems. Expert Rev Vaccines 10: 471-486.
14. Garcon N, Chomez P, Van Mechelen M, (2007) GlaxoSmithKline Adjuvant Systems in vaccines: concepts, achievements and perspectives. Expert Rev Vaccines 6: 723-739.
15. Fox CB, Friede M, Reed SG, Ireton GC, (2010) Synthetic and natural TLR4 agonists as safe and effective vaccine adjuvants. Subcell Biochem 53: 303-321.
16. Gelman AE, Zhang J, Choi Y, Turka LA, (2004) Toll-like receptor ligands directly promote activated CD4+ T cell survival. J Immunol 172: 6065-6073.
17. Hoebe K, Janssen EM, Kim SO, Alexopoulou L, Flavell RA, et al. (2003) Upregulation of costimulatory molecules induced by lipopolysaccharide and double-stranded RNA occurs by Trif-dependent and Trif-independent pathways. Nat Immunol 4: 1223-1229.
18. Shen H, Tesar BM, Walker WE, Goldstein DR, (2008) Dual signaling of MyD88 and TRIF is critical for maximal TLR4-induced dendritic cell maturation. J Immunol 181: 1849-1858.
19. Maxwell JR, Ruby C, Kerkvliet NI, Vella AT, (2002) Contrasting the roles of costimulation and the natural adjuvant lipopolysaccharide during the induction of T cell immunity. J Immunol 168: 4372-4381.
20. McAleer JP, Vella AT, (2008) Understanding how lipopolysaccharide impacts CD4 T-cell immunity. Crit Rev Immunol 28: 281-299.
21. McAleer JP, Rossi RJ, Vella AT, (2009) Lipopolysaccharide potentiates effector T cell accumulation into nonlymphoid tissues through TRIF. J Immunol 182: 5322-5330.
22. Hou S, Hyland L, Ryan KW, Portner A, Doherty PC, (1994) Virus-specific CD8+ T-cell memory determined by clonal burst size. Nature 369: 652-654.
23. Mata-Haro V, Cekic C, Martin M, Chilton PM, Casella CR, et al. (2007) The vaccine adjuvant monophosphoryl lipid A as a TRIF-biased agonist of TLR4. Science 316: 1628-1632.
24. MacKenzie SA, Roher N, Boltana S, Goetz FW, (2010) Peptidoglycan, not endotoxin, is the key mediator of cytokine gene expression induced in rainbow trout macrophages by crude LPS. Mol Immunol 47: 1450-1457.
25. Fang WF, Cho JH, He Q, Lin MC, Wu CC, et al. (2007) Lipid A fraction of LPS induces a discrete MAPK activation in acute lung injury. Am J Physiol Lung Cell Mol Physiol 293: L336-344.
26. Sheehan KC, Lai KS, Dunn GP, Bruce AT, Diamond MS, et al. (2006) Blocking monoclonal antibodies specific for mouse IFN-alpha/beta receptor subunit 1 (IFNAR-1) from mice immunized by in vivo hydrodynamic transfection. J Interferon Cytokine Res 26: 804-819.
27. Hwang SY, Hertzog PJ, Holland KA, Sumarsono SH, Tymms MJ, et al. (1995) A null mutation in the gene encoding a type I interferon receptor component eliminates antiproliferative and antiviral responses to interferons alpha and beta and alters macrophage responses. Proc Natl Acad Sci U S A 92: 11284-11288.
28. Oh JZ, Kurche JS, Burchill MA, Kedl RM, (2011) TLR7 enables cross-presentation by multiple dendritic cell subsets through a type I IFN-dependent pathway. Blood 118: 3028-3038.
29. Hogquist KA, Jameson SC, Heath WR, Howard JL, Bevan MJ, et al. (1994) T cell receptor antagonist peptides induce positive selection. Cell 76: 17-27.
30. Barnden MJ, Allison J, Heath WR, Carbone FR, (1998) Defective TCR expression in transgenic mice constructed using cDNA-based alpha- and beta-chain genes under the control of heterologous regulatory elements. Immunol Cell Biol 76: 34-40.
31. Thompson BS, Mitchell TC, (2004) Measurement of daughter cell accumulation during lymphocyte proliferation in vivo. J Immunol Methods 295: 79-87.
32. Sengupta S, Chilton PM, Mitchell TC, (2005) Adjuvant-induced survival signaling in clonally expanded T cells is associated with transient increases in pAkt levels and sustained uptake of glucose. Immunobiology 210: 647-659.
33. Kamath AT, Pooley J, O'Keeffe MA, Vremec D, Zhan Y, et al. (2000) The development, maturation, and turnover rate of mouse spleen dendritic cell populations. J Immunol 165: 6762-6770.
34. Asselin-Paturel C, Brizard G, Pin JJ, Briere F, Trinchieri G, (2003) Mouse strain differences in plasmacytoid dendritic cell frequency and function revealed by a novel monoclonal antibody. J Immunol 171: 6466-6477.
35. Sathe P, Shortman K, (2008) The steady-state development of splenic dendritic cells. Mucosal Immunol 1: 425-431.
36. Holt PG, Strickland DH, Wikstrom ME, Jahnsen FL, (2008) Regulation of immunological homeostasis in the respiratory tract. Nat Rev Immunol 8: 142-152.
37. Edwards AD, Diebold SS, Slack EM, Tomizawa H, Hemmi H, et al. (2003) Toll-like receptor expression in murine DC subsets: lack of TLR7 expression by CD8 alpha+ DC correlates with unresponsiveness to imidazoquinolines. Eur J Immunol 33: 827-833.
38. Thompson BS, Mata-Haro V, Casella CR, Mitchell TC, (2005) Peptide-stimulated DO11.10 T cells divide well but accumulate poorly in the absence of TLR agonist treatment. Eur J Immunol 35: 3196-3208.
39. Vella AT, McCormack JE, Linsley PS, Kappler JW, Marrack P, (1995) Lipopolysaccharide interferes with the induction of peripheral T cell death. Immunity 2: 261-270.
40. Dufour JH, Dziejman M, Liu MT, Leung JH, Lane TE, et al. (2002) IFN-gamma-inducible protein 10 (IP-10; CXCL10)-deficient mice reveal a role for IP-10 in effector T cell generation and trafficking. J Immunol 168: 3195-3204.
41. Yoneyama H, Narumi S, Zhang Y, Murai M, Baggiolini M, et al. (2002) Pivotal role of dendritic cell-derived CXCL10 in the retention of T helper cell 1 lymphocytes in secondary lymph nodes. J Exp Med 195: 1257-1266.
42. Cekic C, Casella CR, Eaves CA, Matsuzawa A, Ichijo H, et al. (2009) Selective activation of the p38 MAPK pathway by synthetic monophosphoryl lipid A. J Biol Chem 284: 31982-31991.
43. Marrack P, Kappler J, Mitchell T, (1999) Type I interferons keep activated T cells alive. J Exp Med 189: 521-530.
44. Curtsinger JM, Valenzuela JO, Agarwal P, Lins D, Mescher MF, (2005) Type I IFNs provide a third signal to CD8 T cells to stimulate clonal expansion and differentiation. J Immunol 174: 4465-4469.
45. Gonzalez-Navajas JM, Lee J, David M, Raz E, (2012) Immunomodulatory functions of type I interferons. Nat Rev Immunol 12: 125-135.
46. McAleer JP, Zammit DJ, Lefrancois L, Rossi RJ, Vella AT, (2007) The lipopolysaccharide adjuvant effect on T cells relies on nonoverlapping contributions from the MyD88 pathway and CD11c+ cells. J Immunol 179: 6524-6535.
47. Havenar-Daughton C, Kolumam GA, Murali-Krishna K, (2006) Cutting Edge: The direct action of type I IFN on CD4 T cells is critical for sustaining clonal expansion in response to a viral but not a bacterial infection. J Immunol 176: 3315-3319.
48. Longhi MP, Trumpfheller C, Idoyaga J, Caskey M, Matos I, et al. (2009) Dendritic cells require a systemic type I interferon response to mature and induce CD4+ Th1 immunity with poly IC as adjuvant. J Exp Med 206: 1589-1602.
49. Durand V, Wong SY, Tough DF, Le Bon A, (2004) Shaping of adaptive immune responses to soluble proteins by TLR agonists: a role for IFN-alpha/beta. Immunol Cell Biol 82: 596-602.
50. Ahonen CL, Doxsee CL, McGurran SM, Riter TR, Wade WF, et al. (2004) Combined TLR and CD40 triggering induces potent CD8+ T cell expansion with variable dependence on type I IFN. J Exp Med 199: 775-784.
51. Kadowaki N, Ho S, Antonenko S, Malefyt RW, Kastelein RA, et al. (2001) Subsets of human dendritic cell precursors express different toll-like receptors and respond to different microbial antigens. J Exp Med 194: 863-869.
52. Eri R, Kodumudi KN, Summerlin DJ, Srinivasan M, (2008) Suppression of colon inflammation by CD80 blockade: evaluation in two murine models of inflammatory bowel disease. Inflamm Bowel Dis 14: 458-470.
53. Nolan A, Kobayashi H, Naveed B, Kelly A, Hoshino Y, et al. (2009) Differential role for CD80 and CD86 in the regulation of the innate immune response in murine polymicrobial sepsis. PLoS One 4: e6600.
54. Pasare C, Medzhitov R, (2004) Toll-dependent control mechanisms of CD4 T cell activation. Immunity 21: 733-741.
55. Fitzgerald KA, Rowe DC, Barnes BJ, Caffrey DR, Visintin A, et al. (2003) LPS-TLR4 signaling to IRF-3/7 and NF-kappaB involves the toll adapters TRAM and TRIF. J Exp Med 198: 1043-1055.
56. Liu M, Guo S, Hibbert JM, Jain V, Singh N, et al. (2011) CXCL10/IP-10 in infectious diseases pathogenesis and potential therapeutic implications. Cytokine Growth Factor Rev 22: 121-130.
57. Foulds KE, Zenewicz LA, Shedlock DJ, Jiang J, Troy AE, et al. (2002) Cutting edge: CD4 and CD8 T cells are intrinsically different in their proliferative responses. J Immunol 168: 1528-1532.
58. Mitchell TC, Teague TK, Hildeman DA, Bender J, Rees WA, et al. (2002) Stronger correlation of bcl-3 than bcl-2, bcl-xL, costimulation, or antioxidants with adjuvant-induced T cell survival. Ann N Y Acad Sci 975: 114-131.
59. Saibil SD, Jones RG, Deenick EK, Liadis N, Elford AR, et al. (2007) CD4+ and CD8+ T cell survival is regulated differentially by protein kinase Ctheta, c-Rel, and protein kinase B. J Immunol 178: 2932-2939.